NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis → Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (From American Hartford Gold Group) (Ad) Free CSBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.03▼$5.0350-Day Range$9.11▼$10.9652-Week Range$7.19▼$14.68Volume1,377 shsAverage Volume2,239 shsMarket Capitalization$68.36 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaSustainability Get Champions Oncology alerts: Email Address Champions Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside49.1% Upside$7.50 Price TargetShort InterestBearish0.93% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment1.04Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.22 out of 5 starsMedical Sector220th out of 907 stocksBiological Products, Except Diagnostic Industry29th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingChampions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.93% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Champions Oncology has recently decreased by 2.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChampions Oncology has received a 71.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Champions Oncology is -0.81. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 8 news articles for Champions Oncology this week, compared to 11 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders45.69% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 14.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Champions Oncology Stock (NASDAQ:CSBR)Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Read More Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE CSBR Stock News HeadlinesApril 23, 2024 | msn.comChampions Cup final could be bumped from ITV1 to make room for FA CupApril 23, 2024 | msn.comHow to watch Concacaf Champions Cup live streams free: Semifinals are nextApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 20, 2024 | uk.investing.comChampions Oncology Inc (CSBR)April 20, 2024 | yahoo.comDortmund hope for Champions League momentum against LeverkusenApril 20, 2024 | abcnews.go.comRivalries on tap with Barcelona-Chelsea and Lyon-PSG in Women's Champions League semifinalsApril 20, 2024 | msn.comItaly earns 5th Champions League spot for next season because of overall success in EuropeApril 20, 2024 | msn.comValiant and Champions Circle partner with Wolverine Boots for footwear, apparel to benefit NILApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 20, 2024 | msn.comThe Champions League semi-final stars set for summer movesApril 18, 2024 | msn.comHow to beat Manchester City, Jude bellingham reveals after Champions League triumphApril 18, 2024 | msn.comChampions League talking points: Are PSG a team now? Was Xavi wrong?April 18, 2024 | sports.yahoo.comChampions League semi-final schedule revealedApril 18, 2024 | msn.comBayern Munich’s Champions League win over Arsenal offers club, coach Thomas Tuchel and striker Harry Kane redemption arcApril 18, 2024 | apnews.comPSG star Tabitha Chawinga of Malawi overcomes obstacles en route to Champions League successApril 18, 2024 | msn.comChampions League rules leave teams chasing a moving target in the BundesligaApril 18, 2024 | theguardian.comChampions League team of the week: Kimmich breaks record … and ArsenalApril 17, 2024 | finance.yahoo.comWill Champions Oncology (NASDAQ:CSBR) Spend Its Cash Wisely?April 15, 2024 | reuters.comTerzic seeks Dortmund reaction in Champions League return against AtleticoApril 15, 2024 | msn.comChampions League final 2024: When and where the match is and how to watch it on TVApril 15, 2024 | msn.comWhich Premier League teams can qualify for the 2024-25 Champions League, Europa, or Conference Leagues?April 15, 2024 | msn.comChampions Tower Defense Codes For April 2024April 13, 2024 | msn.comPep Guardiola’s $1.26m watch makes headlines after Champions League matchApril 13, 2024 | msn.comHarlequins reach Champions Cup semi-finals with nail-biting win over BordeauxApril 13, 2024 | sports.yahoo.comBayern Munich suffer Kingsley Coman injury blow before Arsenal Champions League deciderApril 13, 2024 | msn.comLeinster banish Champions Cup ghosts as La Rochelle’s three-peat dream emphatically endedApril 13, 2024 | msn.comTottenham see Champions League hopes dented and Brentford finally end winless runSee More Headlines Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/25/2024Fiscal Year End4/30/2024Next Earnings (Estimated)7/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CSBR CUSIPN/A CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$7.50 Low Stock Price Target$7.50 Potential Upside/Downside+47.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net Margins-19.76% Pretax Margin-19.62% Return on Equity-850.72% Return on Assets-32.62% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual Sales$53.87 million Price / Sales1.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book14.94Miscellaneous Outstanding Shares13,590,000Free Float7,383,000Market Cap$69.04 million OptionableOptionable Beta0.39 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesRonnie MorrisPresident Chief Executive Officer & DirectorDavid Barry MillerChief Financial OfficerKarin Abarca HeidemannVice President-Scientific OperationsMichael RitchieChief Commercial OfficerMaria ManciniVice President-PharmacologyKey CompetitorsPrecision BioSciencesNASDAQ:DTILTurnstone BiologicsNASDAQ:TSBXGritstone bioNASDAQ:GRTSElutiaNASDAQ:ELUTInstil BioNASDAQ:TILView All CompetitorsInsiders & InstitutionsAristides Capital LLCSold 9,800 shares on 2/13/2024Ownership: 0.087%Essex Investment Management Co. LLCSold 28,135 shares on 2/8/2024Ownership: 0.568%Daniel Newman MendelsonBought 1,000 shares on 1/12/2024Total: $6,500.00 ($6.50/share)Daniel Newman MendelsonBought 2,944 shares on 1/10/2024Total: $18,576.64 ($6.31/share)Daniel Newman MendelsonBought 1,000 shares on 1/8/2024Total: $6,150.00 ($6.15/share)View All Insider TransactionsView All Institutional Transactions CSBR Stock Analysis - Frequently Asked Questions Should I buy or sell Champions Oncology stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CSBR shares. View CSBR analyst ratings or view top-rated stocks. What is Champions Oncology's stock price target for 2024? 2 brokerages have issued 12-month price targets for Champions Oncology's stock. Their CSBR share price targets range from $7.50 to $7.50. On average, they expect the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price. View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts. Are investors shorting Champions Oncology? Champions Oncology saw a drop in short interest in March. As of March 31st, there was short interest totaling 58,100 shares, a drop of 7.2% from the March 15th total of 62,600 shares. Based on an average daily trading volume, of 7,000 shares, the days-to-cover ratio is currently 8.3 days. Approximately 1.0% of the shares of the company are short sold. View Champions Oncology's Short Interest. When is Champions Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our CSBR earnings forecast. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its earnings results on Tuesday, March, 12th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company had revenue of $12.02 million for the quarter. Champions Oncology had a negative trailing twelve-month return on equity of 850.72% and a negative net margin of 19.76%. What is Ronnie Morris' approval rating as Champions Oncology's CEO? 8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL). This page (NASDAQ:CSBR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
